KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Interest & Investment Income: 2018-2024

Historic Interest & Investment Income for Aquestive Therapeutics (AQST) over the last 7 years, with Dec 2024 value amounting to $3.4 million.

  • Aquestive Therapeutics' Interest & Investment Income fell 68.74% to $306,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 34.21%. This contributed to the annual value of $3.4 million for FY2024, which is 78.94% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Interest & Investment Income of $3.4 million as of FY2024, which was down 78.94% from $16.3 million recorded in FY2023.
  • Aquestive Therapeutics' Interest & Investment Income's 5-year high stood at $16.3 million during FY2023, with a 5-year trough of $99,000 in FY2022.
  • Over the past 3 years, Aquestive Therapeutics' median Interest & Investment Income value was $3.4 million (recorded in 2024), while the average stood at $6.6 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Interest & Investment Income crashed by 79.25% in 2020 and then surged by 16,385.86% in 2023.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Interest & Investment Income stood at $132,000 in 2020, then spiked by 220.45% to $423,000 in 2021, then plummeted by 76.60% to $99,000 in 2022, then soared by 16,385.86% to $16.3 million in 2023, then tumbled by 78.94% to $3.4 million in 2024.